Forte Biosciences Inc (FBRX) - Total Liabilities
Based on the latest financial reports, Forte Biosciences Inc (FBRX) has total liabilities worth $12.99 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Forte Biosciences Inc equity growth rate to track the company's year-over-year net asset growth rate.
Forte Biosciences Inc - Total Liabilities Trend (2015–2024)
This chart illustrates how Forte Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data.
Forte Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Forte Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Value Added Technology Co. Ltd
KQ:043150
|
Korea | ₩170.42 Billion |
|
New World Resources Ltd
AU:NWC
|
Australia | AU$1.75 Million |
|
RADCOM Ltd
F:RAM
|
Germany | €30.87 Million |
|
Cartesian Therapeutics Inc.
NASDAQ:RNAC
|
USA | $436.51 Million |
|
Terra Santa Propriedades Agrícolas S.A.
SA:LAND3
|
Brazil | R$200.80 Million |
|
Sriracha Construction Public Company Limited
BK:SRICHA
|
Thailand | ฿1.58 Billion |
|
Galectin Therapeutics Inc
NASDAQ:GALT
|
USA | $146.00 Million |
|
Jean Co Ltd
TW:2442
|
Taiwan | NT$15.58 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down Forte Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Forte Biosciences Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Forte Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Forte Biosciences Inc (2015–2024)
The table below shows the annual total liabilities of Forte Biosciences Inc from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $9.08 Million | +147.71% |
| 2023-12-31 | $3.67 Million | +15.32% |
| 2022-12-31 | $3.18 Million | +80.83% |
| 2021-12-31 | $1.76 Million | -22.18% |
| 2020-12-31 | $2.26 Million | +18.15% |
| 2019-12-31 | $1.91 Million | -95.75% |
| 2018-12-31 | $44.94 Million | +114.07% |
| 2017-12-31 | $20.99 Million | -25.97% |
| 2016-12-31 | $28.36 Million | +22.79% |
| 2015-12-31 | $23.09 Million | -- |
About Forte Biosciences Inc
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. … Read more